Drugs / Plasmin

Trials 5 · a red edge is where a trial was stopped

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00418483 Mar 2007 → Apr 2010 arterial occlusion Grifols Therapeutics LLC Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT01014975 Nov 2009 → Nov 2013 ischemic stroke Grifols Therapeutics LLC Completed No outcome recorded
Phase 1/2 NCT00347646 Sep 2006 → May 2007 vitreoretinal degeneration Bausch & Lomb Incorporated Terminated No outcome recorded
Phase 22 trials
Phase 2 NCT01222117 Dec 2010 → Dec 2015 peripheral arterial occlusive disease 1 Grifols Therapeutics LLC Completed No outcome recorded
Phase 2 NCT00348439 Apr 2006 → Aug 2007 vitreoretinal degeneration Bausch & Lomb Incorporated Terminated No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as Plasmin ClinicalTrials.gov intervention name — accepted as the source's own label NCT00348439
2

NCT00347646

NCT01222117

Known as Fibrinolisina (humana) ChEMBL registry synonym — accepted as the source's own label CHEMBL1201505
Known as Fibrinolysin (human) ChEMBL registry synonym — accepted as the source's own label CHEMBL1201505
Known as Fibrinolysine (humaine) ChEMBL registry synonym — accepted as the source's own label CHEMBL1201505
Known as Plasmin (Human) Plasmin (Human)NCT01222117
2

NCT01014975

NCT00418483

Modality Protein / enzyme biologic “Human-derived plasmin reconstituted with sterile sodium chloride for intravitreal injection.” NCT00347646
Route Intravitreal “single intravitreal injection” NCT00347646